BMY - Bristol-Myers Squibb Company
Bristol-Myers Squibb Company
430 East 29th Street
14th Floor
New York, NY 10016
United States
212 546 4000
https://www.bms.com
Sector(s): Healthcare
Industry: Drug Manufacturers—General
Full-time employees: 34,300
Key executives
| Name | Title | Pay | Exercised | Year born |
|---|---|---|---|---|
| Dr. Giovanni Caforio M.D. | Chairman & CEO | 5.76M | N/A | 1965 |
| Mr. David V. Elkins | Exec. VP & CFO | 2.72M | 2.83M | 1968 |
| Dr. Christopher S. Boerner Ph.D. | Exec. VP, COO & Director | 2.62M | N/A | 1971 |
| Ms. Sandra Leung Esq. | Exec. VP & Gen. Counsel | 2.66M | N/A | 1961 |
| Mr. Rupert Vessey BCH, BM, DPHIL, M.A. | Exec. VP & Pres of Research | 2.76M | 1.66M | 1965 |
| Mr. Greg Meyers | Exec. VP and Chief Digital & Technology Officer | N/A | N/A | 1973 |
| Mr. Timothy Power | VP & Head of Investor Relations | N/A | N/A | N/A |
| Ms. Cari Gallman | Sr. VP & Chief Compliance and Ethics Officer | N/A | N/A | N/A |
| Ms. Ann M. Powell Judge | Exec. VP & Chief HR Officer | N/A | N/A | 1966 |
| Dr. Fouad Namouni M.D. | Head of Oncology Devel. | N/A | N/A | 1969 |
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Onureg for the treatment of adult patients with AML; Inrebic, an oral kinase inhibitor indicated for the treatment of myelofibrosis; Camzyos for the treatment of adults with symptomatic obstructive HCM to enhance functional capacity and symptoms; Sotyktu for the treatment of adults with moderate-to-severe plaque psoriasis; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane, a protein-bound chemotherapy product. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Corporate governance
Bristol-Myers Squibb Company’s ISS governance QualityScore as of 1 June 2023 is 2. The pillar scores are Audit: 4; Board: 5; Shareholder rights: 3; Compensation: 1.
